Venn Life Sciences Holdings Stock price London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 * | 66.57M 71.88M | Sales 2024 * | 73.39M 79.25M | Capitalization | 229M 248M |
---|---|---|---|---|---|
Net income 2023 * | 10M 10.8M | Net income 2024 * | 10M 10.8M | EV / Sales 2023 * | 2.8 x |
Net cash position 2023 * | 43.31M 46.77M | Net cash position 2024 * | 51.39M 55.49M | EV / Sales 2024 * | 2.43 x |
P/E ratio 2023 * |
22.2
x | P/E ratio 2024 * |
21.1
x | Employees | - |
Yield 2023 * |
1.38% | Yield 2024 * |
0.61% | Free-Float | 60.77% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Director of Finance/CFO | 61 | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
Elaine Sullivan
BRD | Director/Board Member | 63 | 20-11-23 |
1st Jan change | Capi. | |
---|---|---|
+9.15% | 45.97B | |
+53.01% | 43.93B | |
+8.86% | 42.34B | |
-8.59% | 28.27B | |
+18.11% | 27.18B | |
-20.68% | 19.44B | |
+14.15% | 13.83B | |
+31.74% | 12.4B | |
+9.65% | 11.45B |